Monoclonal antibody Gliomab-H

Drug Profile

Monoclonal antibody Gliomab-H

Alternative Names: Gliomab-H

Latest Information Update: 07 Feb 2008

Price : $50

At a glance

  • Originator Viventia Biotech
  • Developer University of Alabama at Birmingham
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Glioma

Most Recent Events

  • 09 Jan 2001 Monoclonal antibody Gliomab-H is available for collaborative partnerships
  • 29 Aug 2000 No-Development-Reported for Glioma in USA (Unknown route)
  • 08 Sep 1998 Profile reviewed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top